Research

NACHO is a clinical trials group that can rapidly design and implement pilot translational research and clinical research initiatives. While many other initiatives will be developed and executed in the future, the collaboration is being launched with the implementation of high-impact clinical trials, complimented by companion biology studies to facilitate prospective collection of biological samples.
The LCH-IV study is an international, multi-center, prospective clinical study for pediatric Langerhans cell histiocytosis.
The NACHO-BIO study is a biology only multi-center study to collect and analyze specimens from patients affected by histiocytic diseases. 
The NACHO-COBI study is a limited-site study of Cobimetinib in pediatric, young adult, and adult LCH patients with recurrent active disease and histiocytic disorders.
The HLHRUXO study is a limited-site study of Ruxolitinib in pediatric and young adult patients with newly diagnosed or relapsed/refractory hemophagocytic lymphohistiocytosis (HLH).

Publications

NACHO aims to share knowledge learned through the consortium's collaborative efforts by publishing results in scientific journals.